Items tagged with Latent TB

Contact with MDR-TB led to latent infection in some children (post)

After contact with a teacher diagnosed with multidrug-resistant pulmonary tuberculosis, 31 children developed latent infection, according to recent study results published in The Pediatric Infectious Disease Journal.

C-reactive protein could identify more HIV+ eligible for anti-TB IPT (post)

A point-of-care test for C-reactive protein (POC-CRP) greatly increased the proportion of HIV-positive Ugandan adults eligible for isoniazid preventive therapy (IPT) compared with the standard World Health Organization (WHO) symptom screen. POC-CRP would also decrease the proportion of HIV patients who need referral for further TB diagnostic testing.

Mobile clinic screening program identified latent TB in high-risk people (post)

Including tuberculin skin test screening as part of a mobile medical clinic identified a number of patients with latent tuberculosis infection among foreign-born individuals with a high risk of infection, according to data from a recent study.

Short latent TB therapy matches standard care (post)

Short courses of rifamycin-containing treatment regimens prevented active tuberculosis as well as standard monotherapy did, researchers reported.

Treatment of latent tuberculosis infection: A network meta-analysis (post)

In many countries with a low incidence of tuberculosis (TB), many new cases emerge as a result of reactivation of latent TB infection (LTBI), which is often acquired in high-incidence areas or from recent exposure in occasional outbreaks. Therefore, such countries have had a renewed interest in LTBI screening and treatment, generally for groups at particularly high risk for reactivation, such as contacts of patients with pulmonary TB, persons who are immunocompromised, and migrants from high-incidence areas.

Sanofi receives FDA approval of Priftin® (rifapentine) tablets for the treatment of latent tuberculosis infection (post)

Following a priority review, the U.S. Food and Drug Administration has approved Priftin® (rifapentine) in combination with isoniazid (INH) for a new indication for the treatment of latent tuberculosis infection (LTBI) in patients two years of age and older at high risk of progression to tuberculosis (TB) disease. Approved in the United States since 1998, Priftin is an antimycobacterial used in combination with one or more antituberculosis drugs for the treatment of active pulmonary TB caused by Mycobacterium tuberculosis.

Short course in latent TB matches standard treatment (post)

Short courses of rifamycin-containing treatment regimens prevented active tuberculosis (TB) as well as standard monotherapy did, researchers reported.

Once weekly combination regimen effective for childhood tuberculosis (post) Interview with:
Dr. Stefan Goldberg MD
Medical Officer in CDC’s Division of Tuberculosis Elimination
Clinical Research Branch

Latent TB prevalence in China may be overestimated (post)

Researchers from the Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing have found tuberculin skin testing may be overestimating the prevalence of latent tuberculosis in China.

How frequent is latent tuberculosis infection in China? (post)

In the Lancet Infectious Disease, Lei Gao and colleagues1 report the results of a large multicentre, prospective cohort study of the prevalence of latent tuberculosis infection in China. The study was done in registered residents (aged ≥5 years) of four sites in rural China with diverse climates, population profiles, and incidences of tuberculosis. Eligible participants were identified by door-to-door survey and the screening process included a questionnaire about demographics and risk factors for tuberculosis, a tuberculin skin test, an interferon-γ release assay (QuantiFERON [QFT]), and digital chest radiography for participants older than 15 years.

Page 1 of 13 · Total posts: 0

1 2 Last→